Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Healthtrust
UBS
Dow
Baxter
Covington
Federal Trade Commission
Argus Health
Julphar

Generated: September 25, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,585,839

« Back to Dashboard

Title:Particles for use in a pharmaceutical composition
Abstract: The invention provides a method of making a composition for inhalation which includes the step of mixing particles of additive material having a diameter of not more than 2 .mu.m with active particles, wherein the additive material is suitable for promoting the dispersal of active particles upon aerolization of a dry powder in a dry powder inhaler.
Inventor(s): Staniforth; John Nicholas (Bath, GB), Morton; David Alexander Vodden (Bath, GB)
Assignee: VECTURA LIMITED (Chippenham, Wiltshire, GB)
Filing Date:Oct 10, 2013
Application Number:14/050,819
Claims:1. A method of making a composition for inhalation which includes the step of mixing particles of additive material having a diameter of not more than 2 .mu.m with active particles, wherein the additive material is suitable for promoting the dispersal of active particles upon aerolisation of a dry powder in a dry powder inhaler, and the step of pressing the particles of additive material to the surfaces of the active particles by a milling step involving compressing the mixture of active and additive particles in a gap of fixed predetermined width, wherein the additive comprises magnesium stearate.

2. A method as claimed in claim 1 in which the additive particles have a diameter of not more than 1.5 .mu.m.

3. A method as claimed in claim 1 or claim 2, wherein the additive material comprises a further hydrophobic material suitable for delaying the dissolution of an active substance in the lung.

4. A method as claimed in claim 1, in which the additive material further comprises a phospholipid.

5. A method as claimed in claim 1, in which the additive material further comprises an amino acid.

6. A method as claimed in claim 1, in which the additive material is soft.

7. A method as claimed in claim 1 in which the additive particles are in the form of agglomerates.

8. A method as claimed in claim 1 in which the additive particles have a bulk density not more than 0.4 gcm.sup.-3.

9. A method as claimed in claim 1 in which the additive particles are in the form of flakes having a thickness of not more than 0.53 .mu.m.

10. A method as claimed in claim 1 further comprising the step of providing large particles of additive material having a MMAD of greater than 2 .mu.m and the step of reducing the size of those particles such that the MMAD of the resulting particles is less than 2 .mu.m.

11. A method as claimed in claim 10 in which the step of reducing the size of the particles of additive material involves the movement of the particles from a region of high pressure to a region of low pressure.

12. A method as claimed in claim 11 in which the step of reducing the size of the particles of additive material involves homogenisation.

13. A method as claimed in any of claims 10 to 12 further comprising, after the step of reducing the size of the particles of additive material, a spray drying step.

14. A method as claimed in any of claims 10 to 13 in which the particles of active material are also present during the step of reducing the size of the particles of additive material.

15. A composition for inhalation comprising particles of an active substance and additive particles, the composition obtained by a method as claimed in claim 1.

16. A composition as claimed in claim 15 which further comprises carrier particles.

17. A composition as claimed in claim 15 which further comprises a propellant for a pressurised metered dose inhaler.

18. A dry powder inhaler comprising a composition as claimed in claim 14.

19. A pressurised metered dose inhaler which comprises a composition as claimed in claim 15.

20. A composition for inhalation comprising particles of an active substance and magnesium stearate particles embedded into the surface of the active particles, the magnesium stearate particles are in the form of flakes having a thickness of not more than 0.5 .mu.m.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Dow
Cerilliant
US Department of Justice
Fish and Richardson
Queensland Health
Julphar
AstraZeneca
Medtronic
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.